Celera Cuts Third Database Deal With Novartis Pharma | GenomeWeb

ROCKVILLE, Md.--Celera Genomics here said it has entered a five-year deal to provide a subscription to its database products and early access to new genomic information to Novartis Pharma. Through the subscription, which includes access to associated bioinformatics tools for viewing, browsing, and analyzing genomics information, Novartis will gain access to Celera's human gene index, its Drosophila genome database, and its human genome database. Celera has also licensed its database products to Pharmacia and Upjohn and Amgen. Terms of the deals have not been announced.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.